ImmunityBio, Inc.
2.4200-0.16 (-6.2%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · IBRX · USD
Key Stats
Market Cap
2.38BP/E (TTM)
-Basic EPS (TTM)
-0.48Dividend Yield
0%Recent Filings
8-K
ImmunityBio settles derivative suits with reforms
ImmunityBio announced preliminary court approval of a settlement for its consolidated shareholder derivative lawsuits, stemming from alleged fiduciary breaches over undisclosed cGMP deficiencies at Anktiva's CMOs that led to a 2023 FDA rejection. The deal requires adopting governance reforms—including appointing a new independent director by December 31, 2025, enhancing disclosure and audit charters, quarterly FDA compliance reports, annual legal reviews, and mandatory employee training—for four years, while releasing all related claims. Shareholders' counsel seeks up to $2.5 million in fees from insurance; final hearing set for November 4, 2025. Reforms bolster oversight, yet litigation risks linger until approval.
8-K
Q2 revenue surges 60%
ImmunityBio reported Q2 2025 revenue of $26.4 million, up 60% from Q1, driven by ANKTIVA sales in BCG-unresponsive NMIBC, with year-to-date sales hitting $42.9 million and 246% unit growth since J-code approval. Cash stood at $153.7 million as of June 30, bolstered by $80 million equity financing in July that could yield up to $96 million more via warrants. Yet regulatory hurdles persist: FDA issued a Refuse to File for papillary NMIBC sBLA, prompting ImmunityBio to weigh RCT initiation against chemotherapy. Momentum builds in lung cancer trials and UK approvals.
10-Q
Q2 FY2025 results
ImmunityBio's Q2 revenue surged to $26.4M from ANKTIVA sales, up 60% q/q and 2,400% y/y (derived), while YTD hit $42.9M, a 3,800% y/y jump (derived), driven by U.S. distribution to specialty pharmacies and drop-ship to end users. Gross margin held steady at ~99.5%, but operating loss narrowed to $71.3M from $99.3M y/y, with R&D steady at $55.2M amid pipeline advances in NSCLC and lymphopenia. Diluted EPS improved to -$0.10 from -$0.20 y/y, reconciling to 888M weighted shares with no anti-dilution. Cash dipped to $137.7M plus $16M securities, offset by $307M revenue interest liability and $492M related-party note at Term SOFR+8%; free cash flow not disclosed in the 10-Q. Yet regulatory hurdles persist in expanding ANKTIVA approvals.
8-K
ImmunityBio raises $80M equity
ImmunityBio secured $80 million in gross proceeds from a registered direct offering of 29.6 million common shares at $2.70 each, plus warrants for another 29.6 million shares at $3.24, closing around July 28, 2025. This bolsters the biotech's $154 million cash pile amid 60% Q2 revenue growth to $26.4 million from ANKTIVA sales, fueling pipeline advances in lung cancer and lymphopenia trials. Yet dilution looms large for shareholders.
8-K
2025 Equity Plan approved
ImmunityBio's stockholders approved the 2025 Equity Incentive Plan on June 18, 2025, replacing the expiring 2015 plan to better attract and retain talent through equity awards. The new plan reserves 46,088,027 shares, plus up to 32,359,674 recycled from the prior plan, aligning employee incentives with shareholder interests. No further awards under the old plan. This bolsters motivation amid biotech competition.
ARTV
Artiva Biotherapeutics, Inc.
4.39-0.34
IBIO
iBio, Inc.
1.54+0.15
IMA
ImageneBio, Inc.
8.79+0.09
IMMX
Immix Biopharma, Inc.
3.72-0.18
IMTX
Immatics N.V.
10.34-0.02
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
INMB
INmune Bio Inc.
1.82+0.00
NWBO
Northwest Biotherapeutics, Inc.
0.23-0.02
TOVX
Theriva Biologics, Inc.
0.31-0.02
UNBX
Unity Biotechnology, Inc.
0.06+0.00